Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Seaport Therapeutics

Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
From Seaport Therapeutics
Via Business Wire
Seaport Therapeutics Presents New Preclinical Data on SPT-320 (Glyph Agomelatine) at the Society of Biological Psychiatry (SOBP) Annual Meeting
From Seaport Therapeutics
Via Business Wire
Seaport Therapeutics to Participate in Upcoming Investor Conferences in April
From Seaport Therapeutics
Via Business Wire
Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
From Seaport Therapeutics
Via Business Wire
Seaport Therapeutics to Participate in Two Upcoming Investor Conferences
From Seaport Therapeutics
Via Business Wire
Seaport Therapeutics Presents New Meta-Analysis Examining Correlations Between Clinical Trial Design Factors and Placebo Response in Major Depressive Disorder Studies
From Seaport Therapeutics
Via Business Wire
Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with Glyph™ Platform
From Seaport Therapeutics
Via Business Wire
Seaport Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Seaport Therapeutics
Via Business Wire
Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
From Seaport Therapeutics
Via Business Wire
Seaport Therapeutics Adds Sandi Peterson to its Board of Directors
From Seaport Therapeutics
Via Business Wire
Seaport Therapeutics Names Lauren White as Chief Financial Officer
From Seaport Therapeutics
Via Business Wire
Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round
From Seaport Therapeutics
Via Business Wire
Seaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors
From Seaport Therapeutics
Via Business Wire
Seaport Therapeutics Appoints Seasoned Executives to Management Team
From Seaport Therapeutics
Via Business Wire
Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
From Seaport Therapeutics
Via Business Wire
Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments
From Seaport Therapeutics
Via Business Wire
Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines
From Seaport Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.